deltatrials
Completed PHASE1 NCT00055991

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

A Multicenter Randomized Double-Blind Trial Of Targretin Capsules Modifying Immunophenotypic Markers Related To Breast Cancer Progression In Breast Tissue From Genetically Identified High Risk Patients

Sponsor: Baylor Breast Care Center

Conditions Breast Cancer
Interventions bexarotene
Updated 7 times since 2017 Last updated: Feb 4, 2013 Started: Sep 30, 2001 Primary completion: Sep 30, 2006 Completion: Sep 30, 2006

Listed as NCT00055991, this PHASE1 trial focuses on Breast Cancer and remains completed. Sponsored by Baylor Breast Care Center, it has been updated 7 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baylor Breast Care Center
  • National Cancer Institute (NCI)
Data source: Baylor Breast Care Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States
  • • San Antonio, United States
  • • Washington D.C., United States